ORTHOReBIRTH
Medical device company developing, manufacturing, and commercializing bioabsorbable microfiber scaffolds for regenerative medicine. Core activities include design and production of cotton-like synthetic bone fillers composed of β-TCP and bioabsorbable polymers, development and commercialization of microfiber cell culture substrates, R&D on BMP-enhanced and antibacterial scaffold formulations, and international distribution through manufacturing and sales partnerships.
Industries
Nr. of Employees
small (1-50)
ORTHOReBIRTH
Georgetown, Texas, United States, North America
Patents
Method for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-12616775-B2
View DetailsMethod for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-11969521-B2
View DetailsMethod for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-10646616-B2
View Details
Method for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-12616775-B2
View DetailsMethod for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-11969521-B2
View DetailsMethod for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method
US-10646616-B2
View DetailsProducts
Cotton-like synthetic bone filler (absorbable β-TCP microfiber scaffold)
Soft, cotton-structured absorbable bone void filler composed of β-TCP and bioabsorbable polymers designed for easy handling, high porosity, and gradual replacement by patient bone.
Stem cell extraction and culture sheet (bioabsorbable microfiber cell-culture substrate)
Commercialized research-use culture sheet composed of bioabsorbable microfibers that facilitates extraction and accelerated proliferation of stem cells and functions as an implantable scaffold.
ReBOSSIS
A soft, cotton-like synthetic bone void filler made of bioresorbable microfibers that easily conforms to bone defects and is absorbed and replaced by native bone.
ReBOSSIS-JS
Artificial bone filler designed for orthopedic surgery.
ReBOSSIS-MS
A variant of the ReBOSSIS-M Series tailored for specific clinical requirements.
ReBOSSIS-J
A tailored version of the ReBOSSIS synthetic bone void filler designed for orthopedic surgery in the Japanese market.
Cotton-like synthetic bone filler (absorbable β-TCP microfiber scaffold)
Soft, cotton-structured absorbable bone void filler composed of β-TCP and bioabsorbable polymers designed for easy handling, high porosity, and gradual replacement by patient bone.
Stem cell extraction and culture sheet (bioabsorbable microfiber cell-culture substrate)
Commercialized research-use culture sheet composed of bioabsorbable microfibers that facilitates extraction and accelerated proliferation of stem cells and functions as an implantable scaffold.
ReBOSSIS
A soft, cotton-like synthetic bone void filler made of bioresorbable microfibers that easily conforms to bone defects and is absorbed and replaced by native bone.
ReBOSSIS-JS
Artificial bone filler designed for orthopedic surgery.
ReBOSSIS-MS
A variant of the ReBOSSIS-M Series tailored for specific clinical requirements.
ReBOSSIS-J
A tailored version of the ReBOSSIS synthetic bone void filler designed for orthopedic surgery in the Japanese market.
Services
Coordination of outsourced production and quality control with contract manufacturers for cotton-like synthetic bone products.
Collaborative research and development partnerships with universities and industry partners for scaffold development, BMP formulation, antibacterial materials, and cell culture substrates.
Coordination of outsourced production and quality control with contract manufacturers for cotton-like synthetic bone products.
Collaborative research and development partnerships with universities and industry partners for scaffold development, BMP formulation, antibacterial materials, and cell culture substrates.
Expertise Areas
- Microfiber scaffold materials for regenerative medicine
- Absorbable synthetic bone fillers for orthopedics and spinal surgery
- Cell-culture substrate development for stem cell extraction and expansion
- BMP-based bone regeneration formulations
Key Technologies
- Electrospinning for microfiber production
- Bioabsorbable polymer microfibers
- β-Tricalcium phosphate (β-TCP) composite scaffolds
- Microfiber-based 3D scaffolds for tissue regeneration
News & Updates
Obtained FDA 510(k) clearance for the synthetic cotton-like bone filler in the trauma field (2014) and additional clearance for spinal use (2017).
Achieved ISO 13485 quality management system certification for medical devices.
Product launched in the United States (2015) and later obtained manufacturing/sales approvals and market entries in Taiwan, India, and Japan; ongoing market expansion activities in Europe.
Released a research-use stem cell extraction and culture sheet leveraging microfiber technology (commercialized December 2018).
Selected for a multi-year commissioned research initiative by NEDO to develop antibacterial cotton-shaped artificial bone (project outcomes reported as promising).
Completed a fundraising round totaling JPY 222,000,000 (announced in 2026).
Obtained FDA 510(k) clearance for the synthetic cotton-like bone filler in the trauma field (2014) and additional clearance for spinal use (2017).
Achieved ISO 13485 quality management system certification for medical devices.
Product launched in the United States (2015) and later obtained manufacturing/sales approvals and market entries in Taiwan, India, and Japan; ongoing market expansion activities in Europe.
Released a research-use stem cell extraction and culture sheet leveraging microfiber technology (commercialized December 2018).
Selected for a multi-year commissioned research initiative by NEDO to develop antibacterial cotton-shaped artificial bone (project outcomes reported as promising).
Completed a fundraising round totaling JPY 222,000,000 (announced in 2026).